natgillin/translations-raw huggingface dataset:
topotecan 0,75 mg/m2 på dag 1-3, 
Cisplatin 50 mg/m2 on day 1 + Topotecan 0.75 mg/m2 on days 1-3, every 21 days
Vinsyre (E334), saltsyre (E507) (til pH-justering), natriumhydroxid (E524) (til pH-justering) og vand til injektionsvæsker. 
tartaric acid (E334), hydrochloric acid (E507) (for pH adjustment), sodium hydroxide (E524) (for pH adjustment) and water for injections.
Sådan bliver Topotecan Teva givet 
How Topotecan Teva is given
Hvert hætteglas indeholder 4 mg topotecan (som hydrochlorid) i 4 ml koncentrat. 
Each vial contains 4 mg topotecan (as hydrochloride) in 4 ml concentrate.
Patienter med forudgående cisplatin-kemo/stråleterapi Cisplatin 
Patients with prior cisplatin chemoradiotherapy Cisplatin Topotecan/Cisplatin
Hvert hætteglas indeholder 1 mg topotecan (som hydrochlorid) i 1 ml koncentrat. 
Each vial contains 1 mg topotecan (as hydrochloride) in 1 ml concentrate.
Topotecan Teva 4 mg/4 ml koncentrat til infusionsvæske, opløsning EU/1/09/552/003- 1 hætteglas 
Topotecan Teva 4 mg/4 ml concentrate for solution for infusion EU/1/09/552/003- 1 vial
Forskel i responsrate (95 % CI) 
Difference in response rate (95% CI)
Efterfølgende doser af topotecan bør ikke gives igen, medmindre neutrofiltallet er ≥ 1 x 109/l, trombocyttallet er ≥ 100 x 109/l og hæmoglobinniveauet er ≥ 9 g/dl (om nødvendigt efter transfusion). 
Topotecan should not be re-administered unless the neutrophil count is ≥ 1 x 109/l, the platelet count is ≥ 100 x 109/l, and the haemoglobin level is ≥ 9 g/dl (after transfusion if necessary).
Koncentrat til infusionsvæske, opløsning 1 hætteglas med 4 ml (4 mg topotecan) 5 hætteglas med ml (4 mg topotecan) 
Concentrate for solution for infusion 1 vial of 4 ml (4 mg topotecan) 5 vials of 4 ml (4 mg topotecan)
Koncentrat til infusionsvæske, opløsning 1 hætteglas med 1 ml (1 mg topotecan) 5 hætteglas med 1 ml (1 mg topotecan) 
Concentrate for solution for infusion 1 vial of 1 ml (1 mg topotecan) 5 vials of 1 ml (1 mg topotecan)
I patienternes egne rapporteringer vha. en ublindet vurdering på en symptomskala i begge studier var oral og intravenøs topotecan forbundet med samme symptomlindring hos patienter med recidiverende, sensitiv SCLC. 
Oral and intravenous topotecan were associated with similar symptom palliation in patients with relapsed sensitive SCLC in patient self reports on an unblinded symptom scale assessment in each of these two studies.
Indlægsseddel: information til brugeren Topotecan Teva 1 mg/1 ml koncentrat til infusionsvæske, opløsning topotecan 
Package leaflet: Information for the user Topotecan Teva 1 mg/1 ml concentrate for solution for infusion topotecan
En læge eller en sygeplejerske vil give dig den fortyndede Topotecan Teva som infusion (intravenøst drop). 
A doctor or nurse will give you the diluted Topotecan Teva solution as an infusion (a drip) usually into your arm over about 30 minutes.
Indlægsseddel: information til brugeren Topotecan Teva 4 mg/4 ml koncentrat til infusionsvæske, opløsning topotecan 
Package leaflet: Information for the user Topotecan Teva 4 mg/4 ml concentrate for solution for infusion topotecan
Ovariecancer og småcellet lungecancer 
Ovarian and small cell lung carcinoma Initial dose
Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 patienter) 
Common (may affect up to 1 in 10 people)
Opbevar Topotecan Teva i køleskab (2-8 °C). 
Store in a refrigerator (2°C - 8°C).
Topotecan Teva 1 mg/1 ml koncentrat til infusionsvæske, opløsning Topotecan Teva 4 mg/4 ml koncentrat til infusionsvæske, opløsning 
Topotecan Teva 1 mg/1 ml concentrate for solution for infusion Topotecan Teva 4 mg/4 ml concentrate for solution for infusion
- hvis du har problemer med lungerne, eller du tidligere har fået strålebehandling eller har fået lægemidler, som påvirker dine lunger (se også punkt 4 ”bivirkninger”). 
The use of Topotecan Teva is not recommended in patients with severe liver impairment; if you currently have lung problems, or if you have received previous radiation treatment or medicines that affected your lungs (also see section 4 ‘Possible side effects'); if you suffer from unusual bruising or bleeding (also see section 4 ‘Possible side effects'); if you are feeling very ill.
Hvis du er i behandling for livmoderhalskræft, kan du få bivirkninger af den anden medicin 
If you are being treated for cervical cancer, you may get side effects from the other medicine (cisplatin) that you will be given along with Topotecan Teva.
(n = 8), unge (n = 3) og yngre voksne (n = 3) med leukæmi. 
The second study included a dose range of 2.0 to 5.2 mg/m2 in children (n = 8), adolescents (n = 3) and young adults (n = 3) with leukaemia.
Ikke anvendt lægemiddel samt affald heraf bør destrueres i henhold til lokale retningslinjer. 
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
Klar lysegul væske. 
Clear pale yellow liquid.
Topotecan Teva 4 mg/4 ml koncentrat til infusionsvæske, opløsning 1 ml koncentrat til infusionsvæske, opløsning, indeholder 1 mg topotecan (som hydrochlorid). 
Topotecan Teva 4 mg/4 ml concentrate for solution for infusion 1 ml of concentrate for solution for infusion contains 1 mg topotecan (as hydrochloride).
Anvendelse af topotecan til disse patienter anbefales ikke (se pkt. 
Use of topotecan in these patient groups is not recommended (see section 4.2).
Hvert hætteglas indeholder 4 ml koncentrat til infusionsvæske, opløsning. 
Each vial contains 4 ml of the concentrate for solution for infusion.
- stærke mavesmerter, feber og muligvis diarré (sjældent med blod) kan være tegn på tyktarmsbetændelse (colitis). 
fever serious decline of your general condition local symptoms such as sore throat or burning sensation when urinating severe stomach pain, fever and possibly diarrhoea (rarely with blood) can be signs of bowel inflammation (neutropenic colitis).
Topotecan Teva 1 mg/1 ml koncentrat til infusionsvæske, opløsning 1 ml koncentrat til infusionsvæske, opløsning, indeholder 1 mg topotecan (som hydrochlorid). 
Topotecan Teva 1 mg/1 ml concentrate for solution for infusion 1 ml of concentrate for solution for infusion contains 1 mg topotecan (as hydrochloride).
Disse bivirkninger er dog tidligere set som følge af behandling med cisplatin-monoterapi og skyldtes ikke topotecan. 
Additional adverse events were seen when topotecan was given in combination with cisplatin, however, these events were seen with cisplatin monotherapy and were not attributable to topotecan.
Sådan gives Topotecan Teva 
How to store Topotecan Teva
Topotecan Teva 1 mg/1 ml koncentrat til infusionsvæske, opløsning topotecan 
Topotecan Teva 1 mg/1 ml concentrate for solution for infusion topotecan
EU/1/09/552/003 - 1 hætteglas EU/1/09/552/004 - 5 hætteglas 
EU/1/09/552/003 - 1 vial EU/1/09/552/004 - 5 vials
Hvert hætteglas indeholder enten 1 ml koncentrat til infusionsvæske, opløsning. 
Each vial contains 1 ml of the concentrate for solution for infusion.
EU/1/09/552/001 - 1 hætteglas EU/1/09/552/002 - 5 hætteglas 
EU/1/09/552/001 - 1 vial EU/1/09/552/002 - 5 vials
Hæmatologiske 
Haematological
I reproduktionstoksiske studier af topotecan til rotter sås ingen virkning på fertiliteten hos hverken hanner eller hunner. 
In reproductive toxicity studies with topotecan in rats there was no effect on male or female fertility; however, in females super-ovulation and slightly increased pre-implantation loss were observed.
Den sædvanlige dosis er 1,5 mg/m2 af kroppens overfladeareal 1 gang dagligt i 5 dage. 
Ovarian and small cell lung cancer The usual dose is 1.5 mg per m2 of body surface area once daily for 5 days.
• Nedsat antal af alle blodlegemer (pancytopeni). 
Decrease in the number of all blood cells (pancytopenia) Allergic or hypersensitivity reactions (including rash).
Ét hætteglas med 1 ml koncentrat indeholder 1 mg topotecan (som hydrochlorid). 
One vial of 1 ml of concentrate contains 1 mg topotecan (as hydrochloride).
Ét hætteglas med 4 ml koncentrat, indeholder 4 mg topotecan (som hydrochlorid). 
One vial of 4 ml of concentrate contains 4 mg topotecan (as hydrochloride).
Topotecan Teva 4 mg/4 ml koncentrat til infusionsvæske, opløsning topotecan 
Topotecan Teva 4 mg/4 ml concentrate for solution for infusion topotecan
EU/1/09/552/004- 5 hætteglas 
EU/1/09/552/004- 5 vials
Det skal du vide, før du begynder at få Topotecan Teva Sådan bliver Topotecan Teva givet Bivirkninger 
What Topotecan Teva is and what it is used for What you need to know before you use Toptecan Teva How to use Topotecan Teva Possible side effects
EU/1/09/552/002- 5 hætteglas 
EU/1/09/552/002- 5 vials
- hvis du er allergisk over for topotecan eller et af de øvrige - hvis du ammer. 
if you are allergic to topotecan or any of the other ingredients of this medicine (listed in section if you are breast-feeding; if your blood cells count is too low.
1 ml koncentrat til infusionsvæske, opløsning, indeholder 1 mg topotecan (som hydrochlorid). 
1 ml of concentrate for solution for infusion contains 1 mg topotecan (as hydrochloride).
- Spørg lægen eller sundhedspersonalet, hvis der er mere, du vil vide. 
If you have any further questions, ask your doctor or nurse.
• Følelse af utilpashed. 
Feeling unwell (malaise).
Et hætteglas med 4 ml koncentrat til infusionsvæske, opløsning, indeholder 4 mg topotecan (som hydrochlorid). 
One vial of 4 ml of concentrate for solution for infusion contains 4 mg topotecan (as hydrochloride).
Meget almindelige bivirkninger (kan forekomme flere end 1 ud af 10 patienter) 
Other side effects with Topotecan Teva include: Very common (may affect more than 1 in 10 people)
Sådan forberedes Topotecan Teva 
How to use Topotecan Teva
Den dosis af Topotecan Teva, som du vil få, vil afhænge af: 
Topotecan Teva is used to treat:
Topotecan Teva frarådes til patienter med svært nedsat nyrefunktion. 
The use of Topotecan Teva is not recommended in patients with severe renal impairment; if you have liver problems.
Fortyndet opløsning 
Disposal
Læs indlægsedlen for cisplatin for yderligere oplysninger om dette lægemiddel. 
For more information about cisplatin, please refer to the corresponding Package Leaflet.
i gruppen, der fik topotecan + cisplatin (95 % CI:: 2,6; 6,1) versus 4,5 mdr. 
In patients (n = 39) with recurrence within 180 days after chemoradiotherapy with cisplatin, the median survival in the topotecan plus cisplatin arm was 4.6 months (95 % CI: 2,6, 6.1) versus 4.5 months (95 % CI: 2.9, 9.6) for the cisplatin arm with a hazard ratio of 1.15 (0.59, 2.23).
Dato for første markedsføringstilladelse: 21 september 2009 Dato for seneste fornyelse: 8 maj 2014 
Date of first authorisation: 21 September 2009 Date of latest renewal: 8 May 2014
Efter åbning: Anvendes inden 2 måneder. 
After opening: Use within 2 months.
Dato for åbning:_______ 
Open date:________
Efter første åbning af flasken skal lægemidlet anvendes indenfor 2 måneder. 
After first opening of the bottle, the medicinal product should be used within 2 months.
Visse andre lægemidler kan påvirke brugen af Clopidogrel BGR eller omvendt. 
Some other medicines may influence the use of Clopidogrel BGR or vice versa.
Blister (OPA/Alu/PVC-Alu) 3 år 
Blister (OPA/Alu/PVC-Alu) 3 years.
Brug af Clopidogrel BGR sammen med mad og drikke Clopidogrel BGR kan tages med eller uden mad. 
Clopidogrel BGR with food and drink Clopidogrel BGR may be taken with or without food.
Imidlertid er det på grund af manglen på interaktionsstudier med andre NSAID'er ikke umiddelbart klart, om der er øget risiko for gastrointestinal blødning med alle NSAID 
However, due to the lack of interaction studies with other NSAIDs it is presently unclear whether there is an increased risk of gastrointestinal bleeding with all NSAIDs.
Mikrokrystallinsk cellulose Pregelatineret majsstivelse Macrogol 6000 
Cellulose, microcrystalline Pregelatinised maize starch Macrogol 6000
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenien KRKA-POLSKA Sp. z o.o, ul. 
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia KRKA-POLSKA Sp. z o.o., ul.
• Hvis du er allergisk over for clopidogrel eller et af de øvrige indholdsstoffer i dette lægemiddel (se afsnit 6) 
• If you are allergic to clopidogrel or any of the other ingredients of this medicine (listed in section 6).
ÆSKE/for blister og flaske 
CARTON/for blisters and bottle
Patienter med sjældne arvelige problemer med galactoseintolerans, total lactase deficiency eller glucose- og/eller galactosemalabsorption, bør ikke anvende dette lægemiddel. 
Patients with rare hereditary problems of galactose intolerance, the total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Indeholder også lactose. 
It also contains lactose.
ETIKET TIL FLASKE 
LABEL FOR BOTTLE
Din læge bør have udskrevet Clopidogrel BGR plus acetylsalicylsyre, hvis du ikke må tage ”orale antikoagulantia”, og du ikke har risiko for alvorlig blødning. 
Your doctor should have prescribed Clopidogrel BGR plus acetylsalicylic acid if you cannot take ‘oral anticoagulants' and you do not have a risk of major bleeding.
Efter åbning: 
After opening:
Hvis du får langvarige blødninger, mens du tager Clopidogrel BGR Hvis du skærer dig eller kommer til skade, kan det tage lidt længere end normalt, før blødningen stopper. 
If you experience prolonged bleeding when taking Clopidogrel BGR If you cut or injure yourself, it may take longer than usual for bleeding to stop.
Równoległa 5, 02-235 Warszaw, Polen KRKA - FARMA d.o.o., V. Holjevca 20/E, 10450 Jastrebarsko, Kroatien 
Równoległa 5, 02-235 Warszawa, Poland KRKA - FARMA d.o.o., V. Holjevca 20/E, 10450 Jastrebarsko, Croatia
Hvis du har taget for meget Clopidogrel BGR Kontakt din læge eller nærmeste skadestue, på grund af den øgede blødningsrisiko. 
If you take more Clopidogrel BGR than you should Contact your doctor or the nearest hospital emergency department because of the increased risk of bleeding.
For flaske 
For bottle
Som forholdsregel bør amning ophøre under behandling med Clopidogrel BGR. 
As a precautionary measure, breast-feeding should not be continued during treatment with Clopidogrel BGR.
Hvis du glemmer at tage en dosis af Clopidogrel BGR, men kommer i tanke om det i løbet af 12 timer, skal du omgående tage tabletten og dernæst tage den næste tablet til sædvanlig tid. 
If you forget to take a dose of Clopidogrel BGR, but remember within 12 hours of your usual time, take your tablet straightaway and then take your next tablet at the usual time.
Advarsler og forsigtighedsregler Hvis nogen af følgende situationer gælder for dig, skal du oplyse det til din læge, før du tager Clopidogrel BGR: 
Warnings and precautions If any of the situations mentioned below apply to you, you should tell your doctor before taking Clopidogrel BGR:
Du bør være blevet informeret om, at ”orale antikoagulantia” er mere effektive mod denne sygdom end acetylsalicylsyre eller kombinationen af Clopidogrel BGR og acetylsalicylsyre. 
You should have been told that ‘oral anticoagulants' are more effective than acetylsalicylic acid or the combined use of Clopidogrel BGR and acetylsalicylic acid for this condition.
Der er dog foretaget et antal retrospektive analyser for at evaluere denne effekt hos patienter i behandling med clopidogrel, for hvem der foreligger resultater af genotyping: CURE (n=2.721), CHARISMA (n=2.428), CLARITYTIMI 28 (n=227), TRITON-TIMI 38 (n=1.477) og ACTIVE-A (n=601) såvel som et antal publicerede kohortestudier. 
There have been a number of retrospective analyses, however, to evaluate this effect in patients treated with clopidogrel for whom there are genotyping results: CURE (n=2721), CHARISMA (n=2428), CLARITY-TIMI 28 (n=227), TRITON-TIMI 38 (n=1477), and ACTIVE-A (n=601), as well as a number of published cohort studies.
Trafik- og arbejdssikkerhed Det er usandsynligt at Clopidogrel BGR påvirker din evne til at køre eller betjene maskiner. 
Driving and using machines Clopidogrel BGR is unlikely to affect your ability to drive or to use machines.
Æsker med 30 og 500 filmovertrukne tabletter i flasker. 
Boxes of 30 and 500 film-coated tablets in bottles are available.
Clopidogrel BGR indeholder clopidogrel og tilhører en lægemiddelgruppe, der kaldes blodfortyndende medicin. 
Clopidogrel BGR contains clopidogrel and belongs to a group of medicines called antiplatelet medicinal products.
Farmakoterapeutisk klassifikation: Antithrombosemidler, trombocytfunktionshæmmende midler eksklusive heparin, ATC-kode: B01AC-04. 
Pharmacotherapeutic group: Antithrombotic agents, platelet aggregation inhibitors excl. heparin, ATC code: B01AC-04.
Før åbning: 
Before opening:
- Øvrige indholdsstoffer: lactose (se afsnit 2 ”Clopidogrel BGR indeholder lactose”), mikrokrystallinsk cellulose, pregelatineret majsstivelse, macrogol 6000, hydrogeneret ricinusolie i tabletkernen og hypromellose (E464), titandioxid (E171), rød jernoxid (E172), talcum og propylenglycol i filmovertrækket. 
- The other ingredients are lactose (see section 2 ‘Clopidogrel BGR contains lactose'), microcrystalline cellulose, pregelatinised maize starch, macrogol 6000 and hydrogenated castor oil in the tablet core and hypromellose (E464), titanium dioxide (E171), red iron oxide (E172), talc and propylene glycol in the film-coating.
• Skal du fortælle din læge, at du er i behandling med Clopidogrel BGR, hvis du skal have foretaget en planlagt operation (også hos tandlægen). 
• You should tell your doctor if a surgery (including dental) is planned.
Derefter er den anbefalededosis én Clopidogrel BGR-tablet på75mg dagligt,som beskrevet ovenfor. 
Then, the recommended dose is one 75 mg tablet of Clopidogrel BGR per day as described above.
Hvis du holder op med at tage Clopidogrel BGR Du må ikke stoppe behandlingen, medmindre din læge fortæller dig, at du skal gøre det. 
Do not stop the treatment unless your doctor tells you so.
Indeholder lactose. 
Also contains lactose.
Tag altid lægemidletnøjagtigt efter lægens eller apotekspersonalets anvisninger. 
Always take this medicine exactly as your doctor or pharmacist has told you.
7 filmovertrukne tabletter: EU/1/09/558/001 14 filmovertrukne tabletter: EU/1/09/558/002 28 filmovertrukne tabletter: EU/1/09/558/003 30 filmovertrukne tabletter: EU/1/09/558/004 50 filmovertrukne tabletter: EU/1/09/558/005 56 filmovertrukne tabletter: EU/1/09/558/006 60 filmovertrukne tabletter: EU/1/09/558/007 84 filmovertrukne tabletter: EU/1/09/558/008 90 filmovertrukne tabletter: EU/1/09/558/009 100 filmovertrukne tabletter: EU/1/09/558/010 
7 film-coated tablets: EU/1/09/558/001 14 film-coated tablets: EU/1/09/558/002 28 film-coated tablets: EU/1/09/558/003 30 film-coated tablets: EU/1/09/558/004 50 film-coated tablets: EU/1/09/558/005 56 film-coated tablets: EU/1/09/558/006 60 film-coated tablets: EU/1/09/558/007 84 film-coated tablets: EU/1/09/558/008 90 film-coated tablets: EU/1/09/558/009 100 film-coated tablets: EU/1/09/558/010
Hvis du blivergravid, mens du tager Clopidogrel BGR, skal du omgående kontakte din læge, da det frarådes at tage Clopidogrel BGR under graviditet. 
If you become pregnant while taking Clopidogrel BGR, consult your doctor immediately as it is recommended not to take clopidogrel while you are pregnant.
30 filmovertrukne tabletter: EU/1/09/558/011 500 filmovertrukne tabletter: EU/1/09/558/012 
30 film-coated tablets: EU/1/09/558/011 500 film-coated tablets: EU/1/09/558/012
Hvis du mener, at ovenstående gælder for dig, eller hvis du overhovedet er i tvivl, så rådfør dig med din læge, inden du tager Clopidogrel BGR. 
If you think any of these apply to you, or if you are in any doubt at all, consult your doctor before taking Clopidogrel BGR.
Clopidogrel BGR indeholder lactose. 
Clopidogrel BGR contains lactose.
En dosis på 0,2 mg/kg opnåede en gennemsnitlig procentvis hæmning på 49,3 % (5 µM ADP-induceret trombocytaggregation), hvilket er sammenligneligt med voksne, der clopidogrel 75 mg/dag. 
The dose of 0.2 mg/kg achieved the mean percent inhibition of 49.3% (5 µM ADP-induced platelet aggregation) which was comparable to that of adults taking clopidogrel 75 mg/day.
Du skal fortsætte med at tage Clopidogrel BGR, så længe udskriver det dig. 
You should take Clopidogrel BGR for as long as your doctor continues to prescribe it.
Acetylsalicylsyre (ASA): ASA ændrede ikke på, at clopidogrel hæmmer den trombocytaggregation som ADP inducerer, men clopidogrel forstærkede virkningen af ASA på den trombocytaggregation som kollagen inducerer. 
Acetylsalicylic acid (ASA): ASA did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation, but clopidogrel potentiated the effect of ASA on collagen-induced platelet aggregation.
Hvis du har haft alvorlige smerter i brystet (hjertekrampe (ustabil angina pectoris) eller hjerteanfald), kan din læge ordinere Clopidogrel BGR i kombination med acetylsalicylsyre, som er et stof, der indgår i mange typer medicin til smertelindring og febersænkning. 
If you have experienced severe chest pain (unstable angina or heart attack), you may be prescribed Clopidogrel BGR in combination with acetylsalicylic acid, a substance present in many medicines used to relieve pain and lower fever.
Du har fået ordineret Clopidogrel BGR til forebyggelse af blodpropper og nedsættelse af risikoen for disse alvorlige hændelser, fordi: - Du lider af åreforkalkning (også kaldet aterosklerose) - og - Du tidligere har haft et hjerteanfald, apopleksi eller kredsløbsforstyrrelser i arme eller ben. 
You have been prescribed Clopidogrel BGR to help prevent blood clots and reduce the risk of these severe events because: - You have a condition of hardening of arteries (also known as atherosclerosis), and - You have previously experienced a heart attack, stroke or have a condition known as peripheral arterial disease.
- Du har haft en alvorlig form for smerter i brystet, som kaldes hjertekrampe (ustabil angina pectoris) eller hjerteanfald (myokardieinfarkt). 
- You have experienced a severe type of chest pain known as ‘unstable angina' or ‘myocardial infarction' (heart attack).
Clopidogrel BGR tages af voksne for at forebygge dannelse af blodpropper (trombi) i blodårer (arterier), som er blevet stive ved en proces kaldet aterotrombose, hvilket kan føre til f.eks. apopleksi, hjerteanfald og død (aterotrombotiske hændelser). 
Clopidogrel BGR is taken by adults to prevent blood clots (thrombi) forming in hardened blood vessels (arteries), a process known as atherothrombosis, which can lead to atherothrombotic events (such as stroke, heart attack, or death).
HDPE flaske (volum: 150 ml) med PP-låg med tørremiddel: 500 filmovertrukne tabletter i en æske. 
HDPE bottle (volume: 150 ml), PP closure with a desiccant: 500 film-coated tablets in a box.
HDPE flaske (volum: 15 ml) med PP-låg med tørremiddel: 30 filmovertrukne tabletter i en æske. 
HDPE bottle (volume: 15 ml), PP closure with a desiccant: 30 film-coated tablets in a box.
Derfor bør samtidig administration af NSAID'er inklusive cox-2-hæmmere og clopidogrelforegå med forsigtighed (se pkt. 
Consequently, NSAIDs including Cox-2 inhibitors and clopidogrel should be co-administered with caution (see section 4.4).
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal du spørge din læge eller apotekspersonalet til råds, før du tager Clopidogrel BGR. 
If you are pregnant or suspect that you are pregnant, you should tell your doctor or your pharmacist before taking Clopidogrel BGR.
Hvis du har glemt at tage Clopidogrel BGR 
If you forget to take Clopidogrel BGR